Novartis vs India: the showdown approaches
With the case due before the Supreme Court on 28 March, the fate of millions who depend on affordable Indian medicines may soon hang in the balance.
At first glance, the case concerns the fact that Novartis has been denied a patent for one of its blockbuster anti-cancer drugs, Glivec, in what is one of the world’s fastest-growing drug markets.
Read more: New Internationalist